Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter / Tate, Jillian R.

12 Issues per year

IMPACT FACTOR 2016: 3.432

CiteScore 2016: 2.21

SCImago Journal Rank (SJR) 2016: 1.000
Source Normalized Impact per Paper (SNIP) 2016: 1.112

See all formats and pricing
More options …
Volume 56, Issue 1


Processing-independent proANP measurement for low concentrations in plasma: reference intervals and effect of body mass index and plasma glucose

Peter D. Mark / Ingrid Hunter / Dijana Terzic / Jens P. Goetze
Published Online: 2017-07-08 | DOI: https://doi.org/10.1515/cclm-2017-0309



Decreased concentrations of pro-atrial-derived natriuretic peptides (proABP) in plasma have been associated with obesity and suggested as a predictor of type 2 diabetes. However, assays for measuring proANP are generally aimed to quantitate higher concentrations of proANP associated with cardiac disease. Therefore, we aimed to measure plasma proANP concentrations in a non-obese Scandinavian reference material and evaluate potential associations of plasma proANP with body mass index (BMI) and plasma glucose, respectively.


We report an optimized processing-independent assay (PIA) for proANP in the lower concentration range. The assay was optimized by raising the amount of radioactive tracer and modifying the mixing ratio of resuspended plasma and buffer. Blood samples from a Scandinavian plasma cohort of 693 healthy subjects were then analyzed and age and gender-specific reference intervals were determined.


Simple linear regression analyses of proANP and both BMI and plasma glucose in fasting subjects displayed insignificant associations. Multiple regression analyses supported these findings. However, a higher median plasma concentration of proANP was noted among women <50 years compared to men, whereas no gender-specific differences were seen in other age groups.


Our results show that in a healthy non-obese population, BMI and plasma glucose in fasting subjects do not affect plasma proANP concentrations. Our method should be considered for future studies on low proANP concentration studies, e.g. in obesity and diabetes.

Keywords: atrial natriuretic peptide; body mass index; natriuretic peptides; pro-atrial natriuretic peptide; processing-independent assay; reference intervals


Epidemiological studies have established that obesity and diabetes are associated with markedly decreased concentrations of N-terminal proANP (NT-proANP) compared to normal body weight as defined by body mass index (BMI) [1]. The bioactive region of proANP, e.g. the C-terminal ANP-28, is known to be implicated in a range of physiological effects in terms of cardiac remodeling and metabolic control [2]. Notably, the increased risk of cardiovascular disease among obese individuals might be partly explained by the relative ANP deficiency seen in obesity, and decreased MR-proANP concentrations have even been suggested to predict the development of type 2 diabetes [3].

The main diagnostic interest for proANP and ANP plasma measurement has so far been to quantitate increased concentrations associated with cardiac disease [4], [5]. However, in the light of the potential importance of reduced proANP concentrations in metabolic disease, there is a need for optimizing methods to accurately reflect changes also in the low concentration range. This new need is underscored by the fact that coexistence of cardiac and metabolic disease is frequent [6] and therefore might interfere with the diagnostic usefulness of atrial and b-type natriuretic peptides in heart failure assessment.

The objective of the present study was partly to optimize our previously reported processing-independent assay (PIA) for proANP [7] and calculate gender- and age-specific reference intervals using established reference material from the Scandinavian countries [8], [9]. Notably, this type of translational analysis quantitates the total amount of the proANP-derived peptide products irrespective of modifications, i.e. all processing products are measured as one quantity in the form of a trypsin-generated fragment (proANP 1–16). For each of these in vitro generated fragments, one ANP mRNA to propeptide translation can be determined. In this way, we are able to report on cardiac expression and secretion without analytical bias from possible modifications and cleavages [10]. Furthermore, we wanted to examine the effect of BMI and fasting plasma glucose on proANP concentrations in this largely non-obese population by simple and multiple regression analyses. In this regard, an impact of glucose concentrations was suggested in a recent report that provided mechanistic insight into the effect of glucose concentrations on cardiac ANP gene expression [11].

Materials and methods


The PIA technology has previously been extensively reported [12]. Briefly, plasma is subjected to treatment with a protease, here trypsin, to enzymatically release a defined fragment from the precursor. This fragment is carefully chosen to be without post-translational modifications or endoproteolytic cleavage sites, where after the fragment is quantified with a conventional immunoassay [13]. For the present proANP method, we used the setup as reported with two major changes: (a) we increased the amount of radioactive tracer from 1000 to 10,000 cpm per test tube, and (b) we changed the mixture for the preanalytical trypsin treatment after the ethanol extraction to one part resuspended plasma extract to one part buffer containing trypsin (concentration). The limit of blank (LoB) was calculated as the mean binding of ten blank replicates+1.645 standard deviations of blanks, limit of detection (LoD) as LoB+1.645 standard deviations of 50-pmol samples and limit of quantification (LoQ) as LoQ≥LoD [14] Imprecision was calculated from samples with different concentrations of proANP covering the calibration curve.

Plasma samples and subject characteristics

We used plasma samples obtained in the Nordic Reference Interval Project Biobank and Database (NOBIDA) [8]. From this material originally consisting of 3002 subjects, plasma from 853 subjects was randomly selected and sought to represent country, gender, and age equally. Due to missing values on all body size parameters and plasma glucose or problems with the proANP analysis, 160 subjects were excluded, and thus 693 subjects (337 men; 356 women) were included in the study. Table 1 shows the clinical and subject characteristics of our study sample and the NOBIDA population. Data on individual gender, age, body height, body weight, plasma glucose in fasting subjects, and proANP concentrations were applied in statistical analyses. BMI was calculated as body weight in kilograms divided by height in meters squared. Subjects are referred to as normal weight, overweight and obese based on a BMI of <25, 25–30, and >30 kg/m2, respectively.

Table 1:

Demographic and clinical characteristics of subjects.


The subjects were divided into sex-specific age groups of <50, 50–70, and >70 years. This division was chosen from an earlier population-based study on pro-B type natriuretic peptide (proBNP) [15]. We visually inspected the distribution pattern of sex- and age-specific proANP concentrations (shown in Figure 1) and excluded four outliers from this evaluation [16], two men aged 27 (2340 pmol/L) and 76 years (1906 pmol/L) and two women aged 34 (1114 pmol/L) and 79 years (2396 pmol/L). Two subjects were removed from the height analysis, two from the weight analyses, and four from the BMI analysis due to missing information. Thirty-four subjects were removed from the plasma glucose analysis (14 subjects were non-fasting and 20 had missing values). The RefVal software [17] based on recommendations of the International Federation of Clinical Chemistry and Laboratory Medicine was used to calculate the 95% reference intervals using the non-parametric bootstrap method. Non-parametric independent tests for comparison of gender-specific median proANP-values in all three age groups and multiple regression analyses for prediction of proANP concentrations were run using SPSS 22. For the comparison between plasma proANP concentrations and body weight, body height, BMI, and fasting plasma glucose concentrations, scatterplots and linear regression analyses were performed by GraphPad Prism 4. A p-value <0.05 was considered statistically significant.

Histograms displaying the distributions of plasma proANP concentrations in sex-specific age-groups after the exclusion of outliers. Each column represents an interval of 50 or 100 pmol/L and the each value on the x-axis indicate the lower border of the interval. The y-axis shows the absolute number of observations within each interval.
Figure 1:

Histograms displaying the distributions of plasma proANP concentrations in sex-specific age-groups after the exclusion of outliers.

Each column represents an interval of 50 or 100 pmol/L and the each value on the x-axis indicate the lower border of the interval. The y-axis shows the absolute number of observations within each interval.


Analytical evaluation

Assay precision was improved considerably by the new setup for the PIA assay. The interassay imprecision coefficients of variation over the lower part of the calibration curve were 3.5% for 50 pmol/L, 4.1% for 100 pmol/L, 4.6% for 250 pmol/L, 6.2% for 500 pmol/L and 10.2% for 1000 pmol/L. Total imprecision was chosen from these data, and accept limit was set to <10%. LoB was 16.9 pmol/L, LoD was 58.6 pmol/L and LoQ was ≥58.6 pmol/L.

Clinical results

The number of subjects and calculated reference intervals including median and ranges for the gender-specific age-groups are shown in the Table 2. Statistical tests of differences of median plasma proANP concentrations are shown in Table 3. Women <50 years displayed significantly higher median proANP concentrations compared to men of the same age group, whereas no differences were observed among 50–70 years and >70 years. No significant association was observed between proANP and BMI or between proANP and plasma glucose. Statistical tests for correlation between phenotype parameters are shown in Table 3. A modest but significant negative correlation is found between proANP concentrations and both height and weight. When gender-specific correlations of proANP and height and weight, respectively, were analyzed, correlations proved insignificant. Two multiple regression analyses with proANP as dependent variable and age, sex, plasma glucose, height and weight as independent variables is shown in Table 3. These results show that the addition of plasma glucose, height and weight to age and sex as independent variables contributes modestly to the explanation of the variation of proANP concentrations in our study population (25% vs. 21%).

Table 2:

Reference intervals of proANP in age- and gender-specific groups.

Table 3:

Statistical tests of sub-group differences and effects on plasma proANP concentrations.


In the present report, we show that proANP concentrations in plasma are not associated with BMI and plasma glucose concentrations, respectively. Also, height and weight have no significant correlation with proANP concentrations in sex-specific analyses. These results are supported by the multiple regression analyses, where the investigated parameters (plasma glucose, height and weight) do not increase the explanatory potential substantially on top of the previously established effects of age and sex.

A negative association between BMI and proANP concentrations in plasma has been described previously [1]. However, the NOBIDA population used in this study differs from the general populations in previous studies in several ways. The NOBIDA population was included based on health criteria, where subjects were excluded for known diabetes or fasting plasma glucose values above levels of diagnostic values for diabetes. In addition, the majority of NOBIDA subjects did not smoke, had no chronic disease, did not receive medication, and had no heredity history of diabetes [9]. As shown in Figure 1, only a small fraction of NOBIDA subjects were obese in terms of BMI. It is therefore a selected population and does not reflect the general Scandinavian population. In this perspective, our results show that, in generally healthy subjects, overweight (until a BMI of 30) per se is not associated with a decrease in proANP concentrations, whereas overweight subjects in non-selected western populations with a higher prevalence of lifestyle risk factors do display decreased proANP concentrations. Taken together, the present results imply that BMI is not the single factor causing a relatively reduced proANP in overweight (BMI <30), but suggest that other factors related to overweight and obesity may be involved.

The individual decrease in the proANP concentration in plasma recently described in relation to an acute rise in plasma glucose [11] cannot be directly translated into our observational study with a non-diabetic range of fasting plasma glucose concentrations. However, among healthy subjects, fasting plasma glucose does apparently not affect the proANP plasma concentration. Whether plasma glucose serves as a predictor of relative proANP deficiency among patients with manifest diabetes still needs to be clarified.

In a comparison of gender in age groups, the median values of proANP concentrations are only significantly higher in women <50 years. Higher concentrations of mid-regional (MR) proANP concentrations in women have been reported previously [18], [19], [20]. The mixed gender-effect on proANP concentrations observed in our study might be partly explained by the lower number of subjects in the age groups of 50–70 and >70 years, which decreases the power of the statistical analyses. Moreover, age may affect proANP concentrations in men and women differently, where the effect of menopause seems particularly relevant [21].

A main advantage of the present study is the optimized PIA method for accurate measurement of plasma proANP. Based on the processing-independent principle, this method comes closer to determine the total translational expression of ANP than assays targeted ANP (a labile analyte), and the method has proven to determine reliable proANP concentrations. Besides, the optimization of the lower concentration range of plasma proANP makes measurement more precise than assays developed to investigate patients with heart failure. Our study design benefits from the inclusion of a largely non-obese and non-smoking population with a low frequency of chronic disease and heredity of diabetes. When these apparent confounders are reduced, the isolated effects of BMI and plasma glucose on proANP values can be interpreted on a more reliable basis.

A limitation to this study is the non-diabetic range of fasting plasma glucose values. Any association between elevated values of fasting glucose among patients with diabetes and proANP expression can therefore not be assessed in this study. Moreover, our study is limited by the paucity of individual demographic and clinical characteristics. The minor proportion of our study population with chronic disease or tobacco consumption can therefore not be excluded and exact comparisons of these characteristics to the characteristics of other reference materials are hampered. Lastly, the number of available samples of subjects >70 years in the NOBIDA population was limited and their reference intervals should be treated with some caution. We, therefore, consider the results as preliminary and should be corroborated in a larger cohort.

In conclusion, we report gender- and age-specific reference intervals for proANP in plasma measured with an optimized PIA for the lower concentration range. In the examined healthy, non-obese population, no association between proANP and BMI and fasting plasma glucose was found. It should therefore be stressed that optimized methods for quantitating low proANP concentrations should be used when performing studies on proANP concentrations in the lower concentration range.


We are grateful to laboratory technician Anne Truesen Asanovski for her expertise regarding assay techniques.


  • 1.

    Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Wilson PW, et al. Impact of obesity on plasma natriuretic peptide levels. Circulation 2004;109:594–600. CrossrefPubMedGoogle Scholar

  • 2.

    Zois NE, Bartels ED, Hunter I, Kousholt BS, Olsen LH, Goetze JP. Natriuretic peptides in cardiometabolic regulation and disease. Nat Rev Cardiol 2014;11:403–12. PubMedWeb of ScienceCrossrefGoogle Scholar

  • 3.

    Magnusson M, Jujic A, Hedblad B, Engström G, Persson M, Struck J, et al. Low plasma level of atrial natriuretic peptide predicts development of diabetes: the prospective Malmö diet and cancer study. J Clin Endocrinol Metab 2012;97:638–45. CrossrefGoogle Scholar

  • 4.

    Gaggin HK, Januzzi JL Jr. Biomarkers and diagnostics in heart failure. Biochim Biophys Acta 2013;1832:2442–50. CrossrefPubMedGoogle Scholar

  • 5.

    Goetze JP, Hansen LH, Terzic D, Zois NE, Albrethsen J, Timm A, et al. Atrial natriuretic peptides in plasma. Clin Chim Acta 2015;443:25–8. Web of ScienceCrossrefPubMedGoogle Scholar

  • 6.

    Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006;355:251–9. CrossrefPubMedGoogle Scholar

  • 7.

    Hunter I, Rehfeld JF, Goetze JP. Measurement of the total proANP product in mammals by processing independent analysis. J Immunol Methods 2011;370:104–10. CrossrefPubMedWeb of ScienceGoogle Scholar

  • 8.

    Rustad P, Simonsson P, Felding P, Pedersen M. Nordic reference interval project bio-bank and database (NOBIDA): a source for future estimation and retrospective evaluation of reference intervals. Scand J Clin Lab Invest 2004;64:431–8. CrossrefPubMedGoogle Scholar

  • 9.

    Felding P, Rustad P, Mårtensson A, Kairisto V, Franzson L, Hyltoft Petersen P, et al. Reference individuals, blood collection, treatment of samples and descriptive data from the questionnaire in the nordic reference interval project 2000. Scand J Clin Lab Invest 2004;64:327–42. CrossrefPubMedGoogle Scholar

  • 10.

    Hunter I, Alehagen U, Dahlström U, Rehfeld JF, Crimmins DL, Goetze JP. N-terminal pro-atrial natriuretic peptide measurement in plasma suggests covalent modification. Clin Chem 2011;57:1327–30. PubMedWeb of ScienceCrossrefGoogle Scholar

  • 11.

    Arora P, Wu C, Hamid T, Arora G, Agha O, Allen K, et al. Acute metabolic influences on the natriuretic peptide system in humans. J Am Coll Cardiol 2016;67:804–12. PubMedCrossrefGoogle Scholar

  • 12.

    Rehfeld JF, Goetze JP. The posttranslational phase of gene expression: new possibilities in molecular diagnosis. Curr Mol Med 2003;3:25–38. PubMedCrossrefGoogle Scholar

  • 13.

    Gøtze JP, Hunter I, Lippert SK, Bardram L, Rehfeld JF. Processing-independent analysis of peptide hormones and prohormones in plasma. Front Biosci (Landmark Ed.) 2012;17:1804–15. CrossrefWeb of SciencePubMedGoogle Scholar

  • 14.

    Armbruster DA, Pry T. Limit of blank, limit of detection and limit of quantitation. Clin Biochem Rev 2008;29(Suppl 1): S49–52. PubMedGoogle Scholar

  • 15.

    Goetze JP, Mogelvang R, Maage L, Scharling H, Schnohr P, Sogaard P, et al. Plasma pro-B-type natriuretic peptide in the general population: screening for left ventricular hypertrophy and systolic dysfunction. Eur Heart J 2006;27:3004–10. PubMedCrossrefGoogle Scholar

  • 16.

    Rifai N, Horvath AR, Wittwer CT. Tietz textbook of clinical chemistry and molecular diagnostics, 6th ed. Elsevier, 2012. Google Scholar

  • 17.

    Solberg HE. The IFCC recommendation on estimation of reference intervals. The RefVal program. Clin Chem Lab Med 2004;42:710–4. PubMedGoogle Scholar

  • 18.

    Clerico A, Del Ry S, Maffei S, Prontera C, Emdin M, Giannessi D. The circulating levels of cardiac natriuretic hormones in healthy adults: effects of age and sex. Clin Chem Lab Med 2002;40: 371–7. PubMedGoogle Scholar

  • 19.

    Hamada M, Shigematsu Y, Takezaki M, Ikeda S, Ogimoto A. Plasma levels of atrial and brain natriuretic peptides in apparently healthy subjects: effects of sex, age, and hemoglobin concentration. Int J Cardiol 2016;228:599–604. PubMedWeb of ScienceGoogle Scholar

  • 20.

    Tzikas S, Keller T, Wild PS, Schulz A, Zwiener I, Zeller T, et al. Midregional pro-atrial natriuretic peptide in the general population/Insights from the Gutenberg health study. Clin Chem Lab Med 2013;51:1125–33. PubMedGoogle Scholar

  • 21.

    Clerico A, Passino C, Emdin M. When gonads talk to the heart sex hormones and cardiac endocrine function. J Am Coll Cardiol 2011;58:627–8. CrossrefPubMedWeb of ScienceGoogle Scholar

About the article

Corresponding author: Jens P. Goetze, MD, DMSc, Professor, Chief Physician, Department of Clinical Biochemistry (KB3014), Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen, Denmark, Phone: +45-3545-2202, Fax: +45-3545-2880

Received: 2017-04-08

Accepted: 2017-05-12

Published Online: 2017-07-08

Published in Print: 2017-11-27

Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

Research funding: An unrestricted research grant from the Novo Nordisk Foundation.

Employment or leadership: None declared.

Honorarium: None declared.

Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.

Citation Information: Clinical Chemistry and Laboratory Medicine (CCLM), Volume 56, Issue 1, Pages 132–137, ISSN (Online) 1437-4331, ISSN (Print) 1434-6621, DOI: https://doi.org/10.1515/cclm-2017-0309.

Export Citation

©2018 Walter de Gruyter GmbH, Berlin/Boston. Copyright Clearance Center

Comments (0)

Please log in or register to comment.
Log in